Hematopoietic capability of CD34+ cord blood cells: a comparison with CD34+ adult bone marrow cells.
The characteristics of hematopoietic progenitor and stem cell (HPC/HSC) populations in mammals vary according to their ontogenic stage. In humans, HPC/HSCs from umbilical cord blood (CB) are increasingly used as an alternative to HPC/HSCs from adult bone marrow (BM) for the treatment of various hematologic disorders. How the hematopoietic activity of progenitor and stem cells in CB differs from that in adult BM remains unclear, however. We compared CD34+ cells, a hematopoietic cell population, in CB with those in adult BM using phenotypic subpopulations analyzed by flow cytometry, the colony-forming activity in methylcellulose clonal cultures, and the repopulating ability of these cells in NOD/Shi-scid (NOD/SCID) mice. Although the proportion of CD34+ cells was higher in adult BM than in CB mononuclear cells, the more immature subpopulations, CD34+ CD33- and CD34+ CD38- cells, were present in higher proportions in CD34+ CB cells. Clonal culture assay showed that more multipotential progenitors were present in CD34+ CB cells. When transplanted into NOD/SCID mice. CD34+ adult BM cells could not reconstitute human hematopoiesis in recipient BM, but CD34+ CB cells achieved a high level of engraftment, indicating that CD34+ CB cells possess a greater repopulating ability. These results demonstrated that human hematopoiesis changes with development from fetus to adult. Furthermore, CD34+ CB cells contained a greater number of primitive hematopoietic cells, including HSCs, than did adult BM, suggesting the usefulness of CD34+ CB cells not only as a graft for therapeutic HSC transplantation but also as a target cell population for ex vivo expansion of transplantable HSCs and for gene transfer in gene therapy.
Ueda
Takahiro
T
Department of Pediatric Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo.|Department of Pediatrics, Nippon Medical School, Tokyo.
Yoshida
Makoto
M
Department of Pediatrics, Hokkaido University School of Medicine, Sapporo.
Yoshino
Hiroshi
H
Department of Pediatric Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo.
Kobayashi
Kimio
K
Central Institute for Experimental Animals, Kawasaki.
Kawahata
Mariko
M
Central Institute for Experimental Animals, Kawasaki.
Ebihara
Yasuhiro
Y
Department of Pediatric Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo.
Ito
Mamoru
M
Central Institute for Experimental Animals, Kawasaki.
Asano
Shigetaka
S
Department of Pediatric Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo.|Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo.
Nakahata
Tatsutoshi
T
Department of Pediatrics, Kyoto University, Kyoto, Japan.
Tsuji
Kohichiro
K
Department of Pediatric Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo. tsujik@ims.u-tokyo.ac.jp.
D000328:Adult; D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis / Q000502:physiology*; D001854:Bone Marrow Cells / Q000166:cytology / Q000276:immunology / Q000502:physiology; D005312:Fetal Blood / Q000166:cytology / Q000276:immunology / Q000502:physiology*; D006085:Graft Survival; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D014183:Transplantation, Heterologous
D018952:Antigens, CD34